3.4 C
Athens
2.5 C
Washington
16.6 C
Melbourne
7.1 C
London
6.3 C
New York
21.2 C
Sydney
Saturday, January 16, 2021

BioNTech: Bill & Melinda Gates Foundation Invested $55 Million In an Infectious Disease Collaboration That Would Reach Up to $100 Million in Total Funding

Must read

Factory in Kilkis Builds Innovative Drone for European and International Standards (VIDEO)

Factory in Kilkis builds a pioneering, for European and international standards, drone, designed by the Laboratory of Fluid and Turbine Engineering of the Aristotle...

Israeli Embassies Around the World on Alert Following Iranian Threats of Retaliation

Israel has put its embassies on high alert around the world, following Iran's threats of retaliation for the assassination of a nuclear scientist near...

Delta and Alitalia Airlines Open First Travel Corridor Between US and Europe since Covid Rules Were Introduced

Delta Air Lines and Alitalia are to launch “quarantine free” flights between the US and Italy, opening up the first travel corridor linking the...

Advisor Resigns from ID2020 Objecting to Blockchain Immunity Passports for COVID-19 – The Statement from ID2020

Elizabeth M. Renieris, a Harvard lawyer on the ID2020 technical advisory committee, has resigned from the ID2020 Alliance. The organization aims to enable digital...

After Pfizer and BioNTech announcement for the Covid-19 vaccine that will be provided to Greece in the comming months, we made a little reserch about the company’s past and it’s published innovations and collaborations till now.

We found the following from BioNTech’s website that may be of interest.

Mainz, Germany, September 4, 2019 – BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that it has signed an agreement with the Bill & Melinda Gates Foundation (which has invested in Moderna in the past as well, always on mRNA based projects..) to develop HIV and tuberculosis programs, further expanding the Company’s infectious disease portfolio. This partnership includes an initial equity investment of $55 million, which is expected to close within the next week. The funds will be used to develop preclinical vaccine and immunotherapy candidates to prevent HIV and tuberculosis infection as well as to lead to durable antiretroviral therapy-free remission of HIV disease. Total funding under the collaboration could reach $100 million through potential future grant funding from the Gates Foundation that would be used to underwrite the evaluation of these candidates in the clinic and support the initiation of new infectious disease projects.

“We are thrilled about the partnership with the Gates Foundation and the outstanding network of infectious disease specialists that it has built,” said Prof. Ugur Sahin, CEO of BioNTech. “Targeting severe infectious diseases such as tuberculosis and HIV infection is in line with our mission to leverage our immunotherapy capabilities not only for cancer but also beyond, in disease areas of high medical need.”

Read Also: The “Unknown” Humble Couple Behind the Pfizer Vaccine. Children of Turkish Immigrants, Billionaires and Aspiring “Saviors” of Humanity.

“Despite remarkable advances in global health since 1990, current approaches to preventing and treating tuberculosis – the world’s leading cause of death from infectious disease – and HIV infection remain inadequate,” said Lynda Stuart, Deputy Director, Vaccines and Human Immunobiology, Discovery and Translational Sciences at the Gates Foundation. “BioNTech’s innovative mRNA-based approach and in-depth understanding of the immune system offer exciting pathways to develop effective new immune-based therapies that could dramatically reduce the global incidence of HIV and tuberculosis. We believe this partnership will add to our portfolio of innovative tools and could make a significant impact.”

Under the terms of the agreement, the collaboration will fund the identification of potential HIV and tuberculosis vaccine and immunotherapy candidates and their pre-clinical development. It will further enable BioNTech to build out its infectious disease infrastructure, including platform development and may allow the Company to initiate three new additional programs within its infectious disease portfolio. All programs will utilize BioNTech’s proprietary platforms and the Company will retain rights for commercialization of the vaccine and immunotherapy candidates in the developed world while providing affordable access to the candidates in developing countries.

More articles

Factory in Kilkis Builds Innovative Drone for European and International Standards (VIDEO)

Factory in Kilkis builds a pioneering, for European and international standards, drone, designed by the Laboratory of Fluid and Turbine Engineering of the Aristotle...

Israeli Embassies Around the World on Alert Following Iranian Threats of Retaliation

Israel has put its embassies on high alert around the world, following Iran's threats of retaliation for the assassination of a nuclear scientist near...

Delta and Alitalia Airlines Open First Travel Corridor Between US and Europe since Covid Rules Were Introduced

Delta Air Lines and Alitalia are to launch “quarantine free” flights between the US and Italy, opening up the first travel corridor linking the...

Advisor Resigns from ID2020 Objecting to Blockchain Immunity Passports for COVID-19 – The Statement from ID2020

Elizabeth M. Renieris, a Harvard lawyer on the ID2020 technical advisory committee, has resigned from the ID2020 Alliance. The organization aims to enable digital...

Latest article

Factory in Kilkis Builds Innovative Drone for European and International Standards (VIDEO)

Factory in Kilkis builds a pioneering, for European and international standards, drone, designed by the Laboratory of Fluid and Turbine Engineering of the Aristotle...

Israeli Embassies Around the World on Alert Following Iranian Threats of Retaliation

Israel has put its embassies on high alert around the world, following Iran's threats of retaliation for the assassination of a nuclear scientist near...

Delta and Alitalia Airlines Open First Travel Corridor Between US and Europe since Covid Rules Were Introduced

Delta Air Lines and Alitalia are to launch “quarantine free” flights between the US and Italy, opening up the first travel corridor linking the...

Advisor Resigns from ID2020 Objecting to Blockchain Immunity Passports for COVID-19 – The Statement from ID2020

Elizabeth M. Renieris, a Harvard lawyer on the ID2020 technical advisory committee, has resigned from the ID2020 Alliance. The organization aims to enable digital...

Event 201: The High-Level Pandemic Exercise on October 18, 2019, in New York (Video)

The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201,...